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Abstract: Background  
Metastatic castration-resistant prostate cancer (mCRPC) is enriched in 
DNA damage repair (DDR) gene aberrations (DDRga). The TOPARP-B trial aims 
to prospectively validate the association between DDRga and response to 
olaparib in mCRPC.  
 
Methods 
In this randomised "pick-the-winner" phase 2 study we recruited 
participants from 17 UK hospitals. Men with progressing mCRPC following 
≥1 taxane chemotherapy regimens and ECOG performance status ≤2 had tumour 
biopsy targeted sequencing. Patients with DDRga were randomised 1:1, by 
computer-generated minimisation method balancing for screening 
circulating tumour cell (CTC) count, to 400mg or 300mg olaparib twice 
daily, given continuously in 4-week cycles until disease progression or 
unacceptable toxicity. Neither participants nor investigators were 
blinded to dose allocation. The primary endpoint response rate (RR) was 
defined as a composite of radiological objective response (as assessed by 
Response Evaluation Criteria in Solid Tumors 1.1), prostate specific 
antigen decline of ≥50% (PSA50) from baseline and/or CTC count conversion 
(≥5 at baseline to <5/7.5ml blood). Confirmed response in consecutive 
assessment after >4 weeks was required for each component. Primary 
analysis was performed in the evaluable population. The trial aimed to 
exclude ≤30% confirmed RR in either arm.  ClinicalTrials.gov, 
NCT01682772; recruitment completed and follow-up ongoing. 
 
Findings 
Overall, 711 patients consented for targeted screening between April 1 
2015 and August 30 2018; 161 had DDRga; 98 were randomised and treated 
(49:49), with 92 evaluable for the primary endpoint (46:46). Median 
follow-up time was 24.8 months (Q1-Q3 16.7 to 35.9 months). Confirmed 
composite RRs were 54% (25/46, 95%CI 39-69%, meeting the threshold for 
primary endpoint) in the 400mg cohort, and 39% (18/46, 95%CI 25-55%) in 
the 300mg cohort. For each component, response rates were: radiological 
400mg 8/33 (24%) vs 300mg 6/37 (16%); PSA50 400mg 17/46 (37%) vs 300mg 
13/43 (30%); CTC count conversion 400mg 15/28 (54%), 300mg 13/27 (48%).  
The most common grade 3-4 adverse event in both cohorts was anaemia 
(300mg 15/46 [30.6%]; 400mg 18/46 [36.7%]). 19 serious adverse reactions 
in 10 patients were reported. One possibly treatment-related death 
(myocardial infarction) occurred after 11 days of  treatment (300mg 
cohort). 
 
Interpretation  
Olaparib has antitumour activity against mCRPC with DDRga, especially 
tumours with BRCA1/2 and PALB2 alterations, supporting implementation of 
mCRPC genomic stratification in clinical practice.  
 
Funding 
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ABSTRACT 
Background  
Metastatic castration-resistant prostate cancer (mCRPC) is enriched in DNA damage repair 
(DDR) gene aberrations (DDRga). The TOPARP-B trial aims to prospectively validate the 
association between DDRga and response to olaparib in mCRPC.  
 
Methods 
In this randomised “pick-the-winner” phase 2 study we recruited participants from 17 UK 
hospitals. Men with progressing mCRPC following ≥1 taxane chemotherapy regimens and 
ECOG performance status ≤2 had tumour biopsy targeted sequencing. Patients with DDRga 
were randomised 1:1, by computer-generated minimisation method balancing for screening 
circulating tumour cell (CTC) count, to 400mg or 300mg olaparib twice daily, given 
continuously in 4-week cycles until disease progression or unacceptable toxicity. Neither 
participants nor investigators were blinded to dose allocation. The primary endpoint response 
rate (RR) was defined as a composite of radiological objective response (as assessed by 
Response Evaluation Criteria in Solid Tumors 1.1), prostate specific antigen decline of ≥50% 
(PSA50) from baseline and/or CTC count conversion (≥5 at baseline to <5/7.5ml blood). 
Confirmed response in consecutive assessment after >4 weeks was required for each 
component. Primary analysis was performed in the evaluable population. The trial aimed to 
exclude ≤30% confirmed RR in either arm.  ClinicalTrials.gov, NCT01682772; recruitment 
completed and follow-up ongoing. 
 
Findings 
Overall, 711 patients consented for targeted screening between April 1 2015 and August 30 
2018; 161 had DDRga; 98 were randomised and treated (49:49), with 92 evaluable for the 
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primary endpoint (46:46). Median follow-up time was 24.8 months (Q1-Q3 16.7 to 35.9 
months). Confirmed composite RRs were 54% (25/46, 95%CI 39-69%, meeting the threshold 
for primary endpoint) in the 400mg cohort, and 39% (18/46, 95%CI 25-55%) in the 300mg 
cohort. For each component, response rates were: radiological 400mg 8/33 (24%) vs 300mg 
6/37 (16%); PSA50 400mg 17/46 (37%) vs 300mg 13/43 (30%); CTC count conversion 
400mg 15/28 (54%), 300mg 13/27 (48%).  The most common grade 3-4 adverse event in 
both cohorts was anaemia (300mg 15/46 [30.6%]; 400mg 18/46 [36.7%]). 19 serious adverse 
reactions in 10 patients were reported. One possibly treatment-related death (myocardial 
infarction) occurred after 11 days of  treatment (300mg cohort). 
 
Interpretation  
Olaparib has antitumour activity against mCRPC with DDRga, especially tumours with 
BRCA1/2 and PALB2 alterations, supporting implementation of mCRPC genomic 
stratification in clinical practice.  
 
Funding 
Cancer Research UK, AstraZeneca, Prostate Cancer UK, Prostate Cancer Foundation, 
Experimental Cancer Medicine Centres Network, and National Institute for Health Research 
Biomedical Research Centres.  
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INTRODUCTION 
Molecular stratification for treatment is not currently standard-of-care for metastatic 
prostate cancers despite the elucidation of marked inter-patient genomic heterogeneity. 
Most therapeutic strategies for advanced prostate cancers target androgen receptor 
signalling; taxane-based chemotherapies and radiopharmaceuticals are also approved
1
. 
While these agents have improved outcomes in the last decade, metastatic prostate 
cancer remains invariably fatal and new therapeutic molecularly-stratified strategies are 
urgently needed. Genomic studies of metastatic prostate cancer have identified multiple 
potentially actionable recurrent genomic aberrations
2-4
, including loss-of-function 
alterations in DNA repair genes in 20-25% of cases, including defects in homologous 
recombination mediated repair genes 
3
. Among these, germline or somatic alterations in 
BRCA2 are the commonest, accounting for 6-12% of cases across studies. These data 
underpin the evaluation of poly-(adenosine diphosphate [ADP]–ribose) polymerase 
(PARP) inhibitors in this disease
5,6
. 
 
Olaparib is an orally-bioavailable inhibitor of the catalytic activity of PARP1 and 
PARP2, which have key roles in DNA defect repair (DDR). Olaparib is approved for 
the treatment of advanced ovarian and breast cancers associated with germline BRCA1 
or BRCA2 mutations
7
. It is also approved as maintenance therapy after response to 
platinum-based chemotherapy for ovarian cancer, indicating benefit from PARP 
inhibition beyond tumours with BRCA1/2 mutations 
8,9
. Further, olaparib has antitumour 
activity in in-vitro and in-vivo models defective in other DDR proteins including 
PALB2, ATM, FANCD2, RAD51, RAD54 and others, although the magnitude of 
preclinical sensitization varies between proteins, with BRCA2 loss being arguably the 
most potent sensitizing event
10,11
.   
 6 
 
To evaluate the antitumour activity of olaparib against metastatic castration resistant 
prostate cancer (mCRPC), we designed TOPARP, an adaptive program of serial phase 2 
clinical trials aimed at identifying predictive biomarkers for response to PARP 
inhibition in mCRPC. In the first trial, TOPARP-A, we identified an association 
between putatively deleterious DDRga and response to olaparib in 49 molecularly 
unselected patients
12
. We present here the results of TOPARP-B, designed to validate 
the observed antitumour activity in mCRPC patients with DDRga. Two different dose 
levels of olaparib were explored: 400mgs twice daily (BID) as used in TOPARP-A, and 
300mg BID, the approved dose for ovarian and breast cancers
13
.  
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METHODS 
Study design and participants 
TOPARP-B is a multi-centre, open-label, investigator-initiated randomised phase 2 trial 
where patients with tumours known to have deleterious DDRga that may sensitize to 
PARP inhibition were randomised to receive olaparib at either 300 mg BID or 400 mg 
BID tablets.  Patients were recruited from 17 UK hospitals (appendix p 2) and 
molecularly pre-selected based on targeted next-generation sequencing (NGS) of 
primary or metastatic prostate cancer biopsies. Eligible patients were men aged 18 years 
or older, with histologically confirmed prostate adenocarcinoma that had developed 
metastasis and castration-resistance, whose tumours had a putatively pathogenic 
mutation or homozygous deletion in a DDR gene that could be associated with 
sensitivity to PARP inhibition. Patients were required to have previously received at 
least one but no more than two taxane-based chemotherapy regimens, regardless of 
prior exposure to novel hormonal agents. Other inclusion criteria included: documented 
prostate cancer progression at trial entry either by prostate-specific antigen (PSA, 
according to the PCWG2 criteria
14
), and/or radiologically (according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1
15
 or by bone scan as per 
PCWG2 criteria); castrate testosterone levels of <50 ng/dL; Eastern Cooperative 
Oncology Group (ECOG) Performance Status ≤2; adequate organ function (including 
haemoglobin ≥9g/dL after protocol amendment in March 15, 2018 (previously 
≥10g/dL), platelets ≥100x109/L, serum creatinine ≤1.5 x times above institutional range 
of normal values and albumin >25 g/dl). Patients previously treated with PARP 
inhibitors, platinum, cyclophosphamide or mitoxantrone were not eligible, as well as 
patients with known symptomatic brain metastasis or untreated cord compressions. 
Baseline count for circulating tumour cells (CTC) (CellSearch® system [Menarini 
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Silicon Biosystems, Inc, Bryn Athin, USA]) had to be >5 cells/7.5 ml blood except for 
patients with radiologically measurable target lesions ≥2cm in diameter on the baseline 
CT scan. A full list of inclusion/exclusion criteria, as well as the complete study 
protocol, is available in the appendix (pp 3-4, 20-148). 
 
Patients provided written informed consent before enrolment, both for the NGS pre-
screening and treatment stages. The study was approved by the London, Surrey Borders, 
Research Ethics Committee (REC reference 11/LO/2019), and co-sponsored by The 
Royal Marsden Hospital and The Institute of Cancer Research (ICR), London, UK. The 
trial was conducted in accordance with the principles of good clinical practice and 
overseen by Independent Data Monitoring (IDMC) and Trial Steering (TSC) 
committees. A Trial Management Group was responsible for the day-to-day running of 
the trial. The Clinical Trials and Statistics Unit at the ICR (ICR-CTSU) had overall 
responsibility for trial coordination, monitoring and analysis.  
 
Randomisation and masking 
Patients were registered into the trial for NGS pre-screening, and subsequently, eligible 
patients were randomly allocated (1:1) to olaparib 300mg BID or olaparib 400mg BID. 
Randomisation was done centrally by the ICR-CTSU via telephone. The allocation 
sequence was generated centrally by computer-generated minimisation algorithm 
derived by ICR-CTSU, with CTC count at screening (≥5 or < 5 cells/7.5 ml blood) as a 
balancing factor. ICR-CTSU staff involved in the randomisation service were not 
involved in the clinical running of the trial or data collection. Neither participants nor 
clinicians were blinded to dose allocation.   
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Procedures 
In the pre-screening part of the study, primary and/or metastatic prostate cancer samples 
were acquired to identify tumours with putatively deleterious DDRga by targeted NGS 
at the Cancer Biomarkers Laboratory at The ICR. DNA was extracted from formalin-
fixed and paraffin embedded (FFPE) tumour blocks using the FFPE Tissue DNA kit 
(Qiagen). Samples that passed quality control criteria were used for library preparation 
using a customized panel (Generead DNAseq Mix-n-Match Panel v2; Qiagen) covering 
113 genes; libraries were read using a MiSeq Sequencer (Illumina). Expanded details on 
sample processing, quality check, and bioinformatics pipelines, as well as the panel 
design, are available in the appendix (pp 5-7).
16
 Patients previously known to have 
germline aberrations were eligible only upon confirmatory tumour NGS testing.  
 
All patients received olaparib at either of the allocated dose levels (300 and 400mgs 
BID) continuously in 4-week cycles until evidence of radiographic progression, 
unacceptable toxicity or patient decision to discontinue. Discontinuation due to clinical 
progression was based on treating clinician decision; discontinuation based solely on a 
rising PSA in the absence of radiographic or clinical progression was discouraged. 
Patients treated with 300mg BID were allowed to increase the olaparib dose to 400mg 
BID at confirmation of disease progression, providing this was considered clinically 
indicated by the treating physician and the patient had not previously required a dose 
reduction for management of toxicity. 
 
Clinical assessments, including review of adverse events, performance status, physical 
examination and routine blood tests (haematology and biochemistry) took place after 2-
weeks of starting treatment, and then at the start of every new 4-weekly cycle. 
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Radiological assessments (CT scan, bone scan) were performed every 12-weeks. CTC 
counts were measured every cycle for the first 12-weeks, and thereafter every 12-weeks. 
CTC counts were centrally analysed, and were not made available to the treating 
physician. PSA assessment was collected every cycle if available, and every 12-weeks 
as a minimum. Blood samples for correlative biomarker studies were taken on a 4-
weekly basis. Repeated tumour biopsies were optional, and pursued when feasible at 
baseline, after 1-4 weeks on therapy and at the time of progression. Adverse events 
were assessed using the National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) version 4. Guidelines on drug interruptions or dose 
reductions for haematological and non-haematological toxicities were implemented as 
outlined in the protocol (appendix pp 20-148). Up to 42-days of temporary interruption 
of treatment was allowed prior to mandating permanent discontinuation. 
 
Outcomes 
The primary endpoint was confirmed tumour response, defined as a composite of: 
objective response by RECIST 1.1 (with PCWG2 caveats) and/or PSA decline of ≥50% 
from baseline and/or conversion of CTC count from ≥5 cells/7.5 ml blood at baseline to 
<5 cells/7.5 ml
17
. To be considered a response for the primary analysis, at least one of 
these three tumour response components, confirmed in a second consecutive assessment 
obtained four or more weeks later, was required.  
 
Protocol-defined secondary endpoints were: radiographic progression-free survival 
(rPFS), defined as time from randomisation to first evidence of radiographic 
progression (by RECIST 1.1 or bone scan as per PCWG2 criteria) or death; time to 
radiographic progression, defined as time from randomisation to first evidence of 
 11 
radiographic progression; progression-free survival, defined as time from randomisation 
until radiographic progression, unequivocal clinical progression or death; overall 
survival (OS), defined as time from randomisation to death by any cause; time to PSA 
progression, defined as a confirmed ≥25% increase and absolute increase of ≥ 2 ng/mL 
in PSA above the nadir (PCWG2); duration of PSA response, defined as the time from 
the first documented ≥50% decline to PSA progression; best percentage change in PSA 
from baseline whilst on treatment, percentage change in PSA from baseline at 12 weeks 
(or earlier if discontinued therapy); proportion of patients with CTC conversion; and the 
safety and tolerability profile of olaparib in men with mCRPC. Pre-specified 
exploratory endpoints included the evaluation of response in patients who escalated 
dose to 400mg BID after progression on 300mg BID. A pharmacokinetics sub-study 
was planned but due to challenges in recruitment it was closed prematurely with no 
analyses pursued. 
 
Statistical Analysis 
Patients were randomised to either 400mg or 300mg BID of olaparib, under a “pick-the-
winner” design18. Each dose cohort was assessed independently for the primary 
endpoint. The sample size to demonstrate the minimum desired antitumour activity was 
based on a one-stage A’Hern design, with RR≤30% for the null hypothesis, and 
RR>50% for the alternative hypothesis (one-sided alpha level 0.05; beta level 0.15). If 
at least 19/44 evaluable patients in a dose cohort responded (43%), then the dose cohort 
would be considered successful. If the 400 mg BID dose cohort was deemed successful, 
the biomarker identified in TOPARP-A, where all patients received 400mg BID, would 
be considered validated. In the event of both dose cohorts being successful, the pick-
 12 
the-winner selection strategy would include consideration of secondary endpoints. No 
formal interim analyses were planned. 
 
For the primary endpoint, the evaluable population was defined as all randomised 
patients who met all of the inclusion and exclusion criteria, and commenced trial 
treatment, unless they discontinued treatment prior to 12-weeks for reasons that were 
not drug or disease related. Sensitivity analyses of the primary endpoint on the ITT (all 
randomised patients) and per protocol (all evaluable patients who received at least one 
cycle of olaparib, and had no major protocol violations) populations were conducted. A 
post-hoc sensitivity analysis on patients with CTC count ≥5 cells/7.5ml blood at 
baseline was performed for comparison with TOPARP-A results. All other efficacy 
analyses were performed on the ITT population.  
 
Analysis of the primary endpoint was triggered when all patients had completed at least 
6-months of treatment (in the absence of prior discontinuation). Evaluable patients who 
discontinued prior to 12-weeks due to progression or toxicity and had no follow-up 
assessments for the primary endpoint were considered non-responders. Response rates 
are presented along with exact two-sided 95% confidence intervals. Local radiological 
response assessment was used for the primary endpoint definition; all RECIST 1.1 
responses were confirmed by central review. Percentage changes from baseline in PSA 
levels and sum of target lesions, are represented in waterfall plots. Time-to-event 
endpoints are summarised by Kaplan-Meier curves, and median times estimated with 
95% confidence intervals. For rPFS and PFS, patients alive and without progression 
were censored at the last scheduled disease assessment on study. For time to 
radiographic progression, patients who did not progress radiologically were censored at 
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the last scheduled disease assessment on study or date of death, whichever occurred 
earlier. Patients alive at the end of follow-up were censored for the analysis of OS. 
Landmark analyses were used to explore the association between CTC conversion at 8- 
and 12-weeks and rPFS and OS.  
 
Subgroup analysis based on different genes of interest were pre-planned for efficacy 
endpoints. Five non-mutually exclusive subgroups were predefined: patients with 
alterations in BRCA1/BRCA2; ATM, CDK12, PALB2, and, lastly, patients with 
alterations in any other gene related to DDR or associated to PARPi sensitivity. Patients 
that had more than one DDRga were included in the analysis of all relevant subgroups.  
 
Toxicity was analysed on all patients who received at least one dose of olaparib, and 
worst grades of adverse events (AEs) during treatment for each dose cohort are 
reported. Serious AEs and deaths observed within 30-days of the last dose of study 
treatment were summarised by dose cohort, as well as the exposure to study drug and 
reasons for discontinuation, dose modification or interruption and /or treatment delay.  
 
The trial was not powered for head-to-head direct comparisons of the two dose-cohorts, 
so tests to compare them are considered hypothesis-generating (e.g. Chi-square test to 
compare response rates, and log-rank test to compare Kaplan-Meier curves). Further 
exploratory analyses are planned in the protocol and will be reported elsewhere. 
Statistical analyses were conducted with the use of Stata software (version 15), on a 
snapshot of the data taken on July 5, 2019. The Statistical Analysis Plan is available in 
the appendix (pp 149-177). 
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This study was registered with ClinicalTrials.gov (NCT01682772) and on the European 
Clinical Trials database (EudraCT 2011-000601-49). 
 
Role of the funding sources 
The funders had no role in the study design, data collection, analysis and interpretation, 
or in the preparation of the report. The corresponding author had full access to all data 
in the study and final responsibility for the decision to submit for publication.  
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RESULTS 
Between April 1 2015 and August 30 2018, 711 patients consented for NGS pre-
screening (Figure 1A). For 30 (4.2%) patients, no samples were made available for 
testing. From 681 patients with at least one sample available, 779 tumour samples were 
analysed (637 [82%] primary tumour samples, 142 [18%] post-castration resistance 
metastatic biopsies). For 89 (13%) patients, biomarker determination was not possible 
due to the sample, or the sequencing data, not fulfilling quality control parameters.  
 
Of the 592 patients with evaluable tissue samples, 161 (27%) had DDRga based on 
NGS, while 431 (73%) did not. An oncoprint summarizing all alterations detected in the 
pre-screening phase of the study is presented in the appendix (p 14). The commonest 
detected DDRga were mutations or homozygous deletions in BRCA2 (44/592, 7.4%), 
ATM (40/592, 6.8%) and CDK12 (33/592, 5.6%). 
 
Ninety-eight DDRga patients were randomised and treated in the two dose-level cohorts 
(49 patients in each cohort). At the time of data snapshot, two patients remained on 
olaparib treatment. More participants were recruited than originally planned, at the 
recommendation of the IDMC, to account for six participants (three in each cohort) who 
were deemed not evaluable (determined ineligible post-randomisation) for the primary 
endpoint analyses. Median follow-up was 24.8 months (Q1-Q3 16.7 to 35.9 months). 
 
Patients baseline characteristics are shown in Table 1; all had previously received 
docetaxel, and 88 (90%) had also been treated with abiraterone acetate (46) and/or 
enzalutamide (56) prior to study entry. The commonest sites for metastases at trial entry 
were bone (82; 84%) and lymph nodes (66; 67%), with measurable soft-tissue disease 
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being present in 75 (77%) patients. The distribution of gene subgroups was largely 
similar between the two dose cohorts, except for CDK12 alterations which was 
imbalanced (31% 300mg vs 12% 400mg). The composition of pre-specified gene 
subgroups per cohort is shown in Figure 1B. Baseline features for each gene subgroup 
are summarised in the appendix (p 8).  
 
For the 92 patients in the evaluable population for the primary endpoint, 70 (76%), 89 
(97%) and 55 (60%) were evaluable for the RECIST 1.1, PSA, and CTC conversion 
components of the response definition respectively. The confirmed composite response 
rates were 25/46 (54%; 95%CI 39-69%) in the 400mg cohort, and 18/46 (39%; 95%CI 
25-55%) in the 300mg cohort (p-value p=0.14) (Table 2).  For each component of the 
primary endpoint, response rates were: radiological response 400mg 8/33 (24%) vs 
300mg 6/37 (16%); PSA response 400mg 17/46 (37%) vs 300mg 13/43 (30%).; CTC 
count conversion 400mg 15/28 (54%), 300mg 13/27 (48%). Based on the first 44 
evaluable patients included in each cohort (as planned initially), there were 25/44 
confirmed responses in the 400mg BID cohort, and 18/44 confirmed responses in the 
300mg BID cohort; hence, the predefined criteria for success was met for 400mg BID 
but not for 300mg BID.  
 
When considering only the 55 evaluable patients with >5 CTC/7.5ml blood at baseline, 
confirmed composite response rates were 61% (17/28, 95%CI 41-79%) in the 400mg 
cohort, and 48% (13/27, 95%CI 29-68%) in the 300mg cohort (see appendix p 9 for 
each individual component). In keeping with previous reports
17,19
, CTC conversions 
post-treatment significantly associated with longer rPFS and OS in landmark analyses 
(appendix p 15). 
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Maximum change from baseline in PSA and sum of target lesions while on allocated 
treatment are presented in Figure 2A and 2B. Overall, 45 ITT patients at 400mg (92%) 
and 46 ITT patients at 300mg (94%) had radiographic progression or death; median 
rPFS was 5.5 months (95%CI 4.4-8.3) in the 400mg cohort, and 5.6 months (95%CI 
3.7-7.7) in the cohort (Figure 2C). At the time of analyses, 39 400mg (80%) and 38 
300mg (78%) patients were deceased, with a median overall survival of 14.3 months 
(95%CI 9.7-18.9) in the 400mg cohort and 10.1 months (95%CI 9-17.7) in the 300mg 
cohort. Further results on the secondary endpoints are summarised in the appendix (pp 
16-18). Time on treatment for each patient is represented in Figure 2D. A summary of 
treatment dose reductions, interruptions and discontinuations by dose cohort is 
presented in the appendix (p 10). 
 
Dose escalation from 300 mg to 400 mg was pursued in 11 patients; at the time of the 
data snapshot, 10 had discontinued treatment: two due to adverse events and eight for 
disease progression. These 11 patients were on treatment with 400mg for a median of 
7.8 weeks (Q1-Q3: 3.7-10.4).  None of these patients achieved a response after dose-
escalation.  
 
The confirmed composite response rates, and by individual components, for each of the 
predefined gene subgroups are shown in Table 2. Further analysis of secondary 
endpoints per gene subgroup can be found in Figure 3 and appendix (pp 11, 19). 
 
The BRCA1/BRCA2 subgroup had the highest response rate (25/30, 83%, 95%CI 65-
94%), and the longest median rPFS of all DDRga subgroups (8.3 months, 95%CI 5.5-
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13.0). The median OS for the BRCA1/BRCA2 subgroup was 17.7 months (95%CI 9.9-
22.2). Of the 32 patients included in this BRCA1/BRCA2 subgroup, 13 had germline 
mutations in BRCA2, six somatic mutations in BRCA2, 11 homozygous deletions in 
BRCA2, and the remaining two cases had mutations in BRCA1 (one germline, one 
somatic). Ten patients in the BRCA1/BRCA2 subgroup (five allocated to 400mg BID, 
five allocated to 300mg BID) remained on treatment for over one year.  
 
Twenty-one patients with suspected deleterious ATM aberrations were treated (one 
patient with homozygous deletion; the rest with germline or somatic mutations that are 
predicted to either result in truncation or missense mutations affecting the kinase 
domain). The composite response rate in patients with ATM aberrations was 37% (7/19; 
95%CI 16-62%), with only 2 of those were RECIST/PSA responses (appendix p 12).  
Median rPFS and OS for the ATM altered subgroup were 5.8 months (95%CI 4.4-10.9) 
and 16.6 months (95%CI 8.9-24.2), respectively.  
 
No confirmed PSA or RECIST responses were observed in the CDK12 mutated 
subgroup, although 5/12 evaluable patients achieved a CTC conversion (including one 
with concomitant BRCA1/2 alteration) (appendix pp 13). Median rPFS was 2.9 months 
(95% CI 2.6-7.5) and median OS was 9.5 months (95%CI 8.2-10.1). 
 
Conversely, 4/7 (57%; 95%CI 18-90%) patients with PALB2 mutations responded to 
treatment, all four had confirmed PSA responses, and two of them also had confirmed 
radiological responses. The median rPFS and OS in this subgroup were 5.3 months and 
13.9 months respectively (95% CI could not be estimated due to small number of 
patients/events). 
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Lastly, 21 patients were evaluated as part of the subgroup with “other gene alterations”. 
The composite response rate in this subgroup was 20% (4/20 patients, 95%CI 6-44), 
with median rPFS of 2.8 months (95%CI 2.6-4.3) and median OS of 7.7 months 
(95%CI 4.3-19.1). PSA responses were seen in one patient whose tumour had a somatic 
nonsense mutation in FANCA and one patient with a CHEK2 mutation. 
 
The safety population included all 98 patients treated. The tolerability profile was in 
line with what has been previously reported for olaparib and other PARP inhibitors
20-22
 
(Table 3). Anaemia was the most common treatment-emergent adverse event (69%), 
with 34% experiencing G3-4 anaemia. Fatigue was also common (54.1%; 7% grade 3-
4). Grade 3-4 gastrointestinal toxicities were rare (1% nausea, 2% decreased appetite, 
2% diarrhoea). Anaemia was the commonest AE leading to dose reductions; 18 (37%) 
patients in the 400mg cohort, and six (12%) in the 300mg cohort, required at least one 
dose reduction (appendix p 10). Eight patients achieving a response while on 400mg, 
continued to respond for more than 6-months after dose reduction to 300mg or lower. 
Overall, 18/98 (19%) patients were permanently discontinued from olaparib treatment 
due to AE.  
 
A total of 107 serious adverse events were reported in 49 (50%) patients, with 19 
serious adverse reactions (SAR, possibly related to study drug, 11 in 300mg, 8 in 
400mg) in 13 patients. The commonest SAR was anaemia (6 in 300mg, 5 in 400mg). 
Four SAR were considered suspected unexpected (SUSAR, two in each dose cohort 
group), including a patient diagnosed with myelodysplasia after 6.5 months of 300mg 
olaparib. This patient developed acute myeloid leukaemia after olaparib discontinuation. 
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One 300mg patient (2%) died due to a myocardial infarction, assessed as possibly drug 
related, after 11-days of treatment. All other deaths were unrelated to treatment.   
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DISCUSSION 
TOPARP-B has confirmed the antitumour activity of olaparib against metastatic 
prostate cancers (mPC) with specific DDRga. The number of composite responses 
observed in the 400mg BID cohort met the predefined criteria for success, validating the 
biomarker identified in TOPARP-A
12
. Overall, the data suggest that both drug dose and 
the specific DDR gene aberration type may matter to antitumour activity since the 
composite response rate at the 300mg BID was lower and did not reach predefined 
criteria for success. The antitumour activity observed varied considerably for different 
DDRga, with the most impressive antitumour activity seen in the BRCA1/BRCA2-
altered subgroup.  
 
Despite randomisation, there was an imbalance in CDK12 aberrations between cohorts, 
with an enrichment for these in the 300mg cohort. This may explain, at least in part, the 
inferior composite response rate in the 300mg cohort
4,23
. The rationale to explore these 
two dose levels originated from prior clinical observations indicating a dose-response 
relationship for olaparib between 100mg BID and 400mg BID, although this dose 
increase is associated with increased toxicity 
24,25
. In keeping with this, 37% patients at 
400mg BID had to dose reduce to 300mg BID, most commonly due to anaemia; all 
these data would need to be considered when assessing the optimal dose of olaparib for 
prostate cancer care.  
 
These results support the implementation of routine genomic testing of metastatic 
prostate cancer, to detect DNA repair defects for PARP inhibition. In previous studies, 
we reported an enrichment for germline inherited mutations in DDR genes in this 
mCRPC population
26
, which has led to a recommendation of broad germline NGS 
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testing for all men suffering from mPC per NCCN guidelines. The antitumour activity 
demonstrated herein for olaparib in mCRPC patients with both germline and somatic 
aberrations of BRCA2 now supports the implementation of NGS testing of tumour 
samples.  
 
Antitumour activity was also observed in other DDRga subgroups. Responses in 
tumours with PALB2 mutations were frequent (4/7 patients), although the low 
prevalence of these mutations means that further data are required to confirm these 
findings. Clinical qualification of low-prevalence biomarkers is challenging in the 
pursuit of precision medicine approaches; the validation of genomic signatures
23,27
 or 
functional biomarkers
28
 that identify tumours with defective homologous-
recombination, regardless of the mutated gene of origin, could help move the field 
forward, but such assays have not been yet validated in prostate cancer. 
 
Conversely, germline and somatic ATM aberrations are common in mPC; ATM 
functions as a cell cycle checkpoint, preventing cell cycle progression in the presence of 
DNA damage rather than directly mediating repair unlike BRCA2 and PALB2. In the 
TOPARP-A trial, 5 patients had ATM aberrations in tumour biopsies: 2 of these had a 
PSA response, and a further 2 achieved a CTC conversion. Preliminary reports suggest 
that rucaparib, another PARP inhibitor, resulted in few PSA falls in patients with ATM 
aberrations
29
. In TOPARP-B, we treated 21 patients with suspected deleterious ATM 
aberrations; two of them achieved a RECIST/PSA response, and several others had 
CTC counts conversions following therapy. CTC count falls seen in this sub-group 
associated with longer duration on trial, tumour shrinkage by RECIST and PSA falls 
(appendix p 12), as was the case for the overall TOPARP-B population, with CTC 
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conversions robustly associating with longer rPFS and OS. Overall, these data indicate 
that the antitumour activity of olaparib in ATM loss mCRPC is less than that for BRCA 
altered tumours; nevertheless, a subset of these patients with ATM altered mCRPC 
appear to derive benefit. Detection of ATM alterations alone may, however, be 
insufficient to identify these sensitive tumours. Further studies, as well as the study of 
rational drug combinations, are now needed to elucidate how to best evaluate and treat 
mCRPC with ATM alterations. Ongoing exploratory analysis from this trial will look 
into further characterization of exceptional responses within each gene-defined 
subgroup to optimize patient stratification.  
 
We do acknowledge limitations to this study. While the utilization of targeted NGS 
facilitates the clinical implementation of patient stratification, this may be insufficient to 
capture more complex aberrations resulting in PARPi sensitivity. Moreover, as all 
patients in this study had DDRga and received olaparib, we are not able to fully 
differentiate the predictive value versus the prognostic impact on of the survival data. 
Randomised trials including biomarker-positive and biomarker-negative patients are 
more able to clinically qualify a putative predictive biomarker.  
 
Nonetheless, these TOPARP results have overall driven the design and conduct of 
multiple registration trials of PARP inhibitors in mCRPC that are likely to guide the 
clinical use of PARP inhibitors in mPC in the future. Most of these studies aim to 
validate PARP inhibition as a precision medicine strategy for prostate cancers with 
DDRga; other studies, in parallel, explore the addition of PARP inhibitors to standard-
of-care AR targeting agents, based on results from a phase II clinical trial which has 
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been reported to indicate that a broader target population may benefit from these 
agents
30
. 
 
In conclusion, these TOPARP-B data have confirmed the antitumour activity of 
olaparib against mPC with certain DDRga. The high response rates observed in patients 
with mCRPC with germline or somatic BRCA1/2 aberrations, and the durability of 
many of these responses, support the use of olaparib in this sub-population. The 
antitumour activity observed against tumours with ATM, PALB2, FANCA or CHEK2 
aberrations suggest that PARPi may have a role as a single agent or in rational 
combinations against these other mPC subtypes, although further data are needed to 
precisely assess the clinical relevance of each of these different DDRga in prostate 
cancer. 
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Figure legends 
Figure 1. (A) CONSORT Flow diagram of patient disposition in the TOPARP-B trial 
(B) Oncoprint of mutations and homozygous deletions in DDR genes that led to trial 
inclusion for the IIT population (n=98)**.  
DDRga= Defective DNA Repair Gene aberration  
* Non-mutually exclusive subgroups: One patient treated at 300mgs BID had BRCA1/2, 
CDK12 & ‘Other mutations’ (300mg); two further 300 mg patients had both PALB2 & 
‘Other mutations’. 
** The BRCA2 K3226* variant was not considered sufficient for patients to be 
considered eligible; however, one patient with a BRCA2 K3226* variant was included 
due to evidence of concomitant loss of the contralateral allele. 
 
Figure 2. Antitumour activity by allocated dose cohort (IIT population): (A) Best 
percentage change from baseline in PSA whilst on allocated treatment; (B) Best 
percentage change from baseline in sum of target lesions (RECIST 1.1) whilst on 
allocated treatment; (C) Radiographic Progression-Free Survival; (D) Swimmers plot of 
time on treatment for each patient, indicating periods of treatment interruptions, dose 
reductions or dose-escalations (in the 300mg dose cohort).   
 
Figure 3. Antitumour activity by gene subgroup (IIT population, pooled 300mg and 
400mg BID cohorts): (A) Best percentage change from baseline in PSA whilst on 
allocated treatment; (B) Best percentage change from baseline in sum of target lesions 
(RECIST 1.1) whilst on allocated treatment; (C) Radiographic Progression-Free 
Survival; (D) Swimmers plot of time on treatment for each patient.  
(*) indicate patients with different mutations qualifying for more than one subgroup. 
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Table 1. Baseline characteristics of TOPARP-B patients in the ITT population, 
presented by dose cohort 
 
Total (N=98) 
Dose group 
300 mg   
(N=49) 
400 mg  
(N=49) 
Age at trial entry, mean (SD) 67.6 (7.6) 67.7 (7.4) 67.4 (7.8) 
Years from initial diagnosis - median 
(Q1-Q3) 
4.6 (2.8-7) 3.5 (2.4-6.4) 5.2 (3.6-7.3) 
Years from diagnosis of CRPC - median 
(Q1-Q3) 
2.6 (1.6-4) 2.4 (1.2-3.7) 3.0 (1.8-4 ) 
Metastatic disease at diagnosis, n (%)       
Yes 49 (50%) 24 (49%) 25 (51%) 
No 45 (45.9%) 24 (49%) 21 (42.9%) 
Not available 4 (4.1%) 1 (2%) 3 (6.1%) 
Gleason score at diagnosis, n (%) 
      
≤7 19 (19.4%) 4 (8.2%) 15 (30.6%) 
≥8 71 (72.4%) 42 (85.7%) 29 (59.2%) 
Not available 8 (8.2%) 3 (6.1%) 5 (10.2%) 
Previous treatment for PC, n (%)       
Prostatectomy 13 (13.3%) 7 (14.3%) 6 (12.2%) 
Radical radiotherapy 43 (43.9%) 22 (44.9%) 21 (42.9%) 
Biphosphonates 4 (4.1%) 2 (4.1%) 2 (4.1%) 
Radium 223 14 (14.3%) 6 (12.2%) 8 (16.3%) 
Docetaxel 98 (100%) 49 (100%) 49 (100%) 
Cabazitaxel 37 (37.8%) 15 (30.6%) 22 (44.9%) 
Abiraterone 46 (46.9%) 24 (49%) 22 (44.9%) 
Enzalutamide 56 (57.1%) 27 (55.1%) 29 (59.2%) 
Abiraterone and/or Enzalutamide 88 (89.8%) 43 (87.8%) 45 (91.8%) 
Evidence of progression at trial entry, n 
(%) 
      
PSA only 27 (27.6%) 15 (30.6%) 12 (24.5%) 
Radiographic progression (+/- PSA 
progression) 
71 (72.4%) 34 (69.4%) 37 (75.5%) 
Site of metastatic disease at trial entry, 
n (%) 
(1)        
Lung 8 (8.2%) 4 (8.2%) 4 (8.2%) 
Lymph nodes 66 (67.3%) 34 (69.4%) 32 (65.3%) 
Liver 23 (23.5%) 11 (22.4%) 12 (24.5%) 
Bone 82 (83.7%) 41 (83.7%) 41 (83.7%) 
PSA at trial entry (ng/ml) – median (Q1-
Q3) 
154.8  
(45.5-472.0) 
151.5  
(49.0-446.0) 
158.0  
(45.5-472.0) 
CTC count at trial entry, n (%) n % n % n % 
CTC<5 34 (34.7%) 17 (34.7%) 17 (34.7%) 
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Total (N=98) 
Dose group 
300 mg   
(N=49) 
400 mg  
(N=49) 
CTC >= 5 63 (64.3%) 31 (63.3%) 32 (65.3%) 
Not available 
(2) 1 (1%) 1 (2%) 0 (0%) 
RECIST soft tissue disease, n (%)  
      
Bone lesions only  10 (10.2%) 5 (10.2%) 5 (10.2%) 
Non-measurable disease only (+/- bone 
lesions) 
13 (13.3%) 5 (10.2%) 8 (16.3%) 
Measurable disease (+/- bone lesions) 75 (76.5%) 39 (79.6%) 36 (73.5%) 
DDRga gene subgroup, n (%)
(3) n % n % n % 
BRCA1/2 32 (32.7%) 15 (30.6%) 17 (34.7%) 
ATM 21 (21.4%) 10 (20.4%) 11 (22.5%) 
CDK12 21 (21.4%) 15 (30.6%) 6 (12.4%) 
PALB2 7 (7.1%) 3 (6.1%) 4 (8.2%) 
Other 21 (21.4%) 10 (20.4%) 11 (22.5%) 
Q1: 25% percentile, Q3: 75% percentile 
(1) More than one site could be reported. 
(2) Screening CTC assessment not possible due to CTC kit shortage. Patient allowed to be 
randomised as he had RECIST 1.1 measurable disease; for randomisation CTC assumed <5 but 
patient was unevaluable for CTC response. 
(3) Non-mutually exclusive subgroups: one 300mg cohort patient had BRCA1/2, CDK12 and 
‘Other mutations’, and two 300 mg cohort patients with PALB2 mutations also had other 
mutations (in MSH2 and NBN respectively). 
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Table 2. Overall antitumour activity in patients with DDRga, by dose cohort and by gene subgroup (evaluable population; confirmed 
responses) 
 
  
Composite  
overall response 
RECIST 1.1  
Objective Response 
PSA fall ≥50% CTC conversion 
RECIST 1.1  
or PSA response 
  resp/n RR 95% CI resp/n % 95% CI resp/n % 95% CI resp/n % 95% CI resp/n % 95% CI 
Evaluable patients 43/92 46.7 36.3-57.4 14/70 20.0% 11.4-31.3 30/89 33.7% 24.0-44.5 28/55 50.9% 37.1-64.6 32/92 34.8% 25.1-45.4 
    
 
    
 
  
 
 
 
  
 
  
 
 
  
By dose cohort:   
 
    
 
  
   
  
 
  
  
  
300 mg BID 18/46 39.1 25.1-54.6 6/37 16.2% 6.2-32.0 13/43 30.2% 17.2-46.1 13/27 48.1% 28.7-68.1 13/46 28.3% 16.0-43.5 
400 mg BID 25/46 54.3 39.0-69.1 8/33 24.2% 11.1-42.3 17/46 37.0% 23.2-52.5 15/28 53.6% 33.9-72.5 19/46 41.3% 27.0-56.8 
    
 
    
 
  
   
  
 
  
  
  
By gene subgroup
¥
   
 
    
 
  
   
  
 
  
  
  
BRCA 1/2 25/30 83.3 65.3-94.4 11/21 52.4% 29.8-74.3 23/30 76.7% 57.7-90.1 17/22 77.3% 54.6-92.2 24/30 80.0% 61.4-92.3 
ATM 7/19 36.8 16.3-61.6 1/12 8.3% 0.2-38.5 1/19 5.3% 0.1-26.0 5/10 50.0% 18.7-81.3 2/19 10.5% 1.3-33.1 
CDK12 5/20 25.0 8.7-49.1 0/18 0.0% 0-18.5* 0/20 0.0% 0-16.8* 5/12 41.7% 15.2-72.3 0/20 0.0% 0-16.8* 
PALB2 4/7 57.1 18.4-90.1 2/6 33.3% 4.3-77.7 4/6 66.7% 22.3-95.7 0/2 0.0% 0-84.2* 4/7 57.1% 18.4-90.1 
Other 4/20 20.0 5.7-43.7 0/17 0.0% 0-19.5* 2/17 11.8% 1.5-36.4 3/11 27.3% 6.0-61.0 2/20 10.0% 1.2-31.7 
Resp/n: number of observed responses / number of evaluable patients; RR: response rate, 95% CI: 95% confidence interval. *One-sided exact binomial 95% confidence intervals 
¥
Non-mutually exclusive subgroups: One patient treated at 300mgs BID had BRCA1/2, CDK12 & ‘Other mutations’ (300mg); two further 300 mg patients had both PALB2 & ‘Other 
mutations’. These patients have been included in analysis for each subgroup separately. For the gene subgroup analyses, dose cohorts have been pooled. 
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Table 3 – Treatment emergent adverse events, by dose cohort  
Any grade 1-2 event occurring in ≥10% of patients is reported. All grade 3, 4, and 5 events are 
reported. 
*Includes one G5 event (myocardial infarction), grouped with G4 for conciseness.  
  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
Anaemia 16 (32.7) 14 (28.6) 1 (2.0) 19 (38.8) 18 (36.7) 0 
Fatigue 19 (38.8) 3 (6.1) 0 27 (55.1) 4 (8.2) 0 
Back pain 13 (26.5) 4 (8.2) 0 11 (22.4) 3 (6.1) 0 
Nausea 17 (34.7) 1 (2.0) 0 13 (26.5) 0 0 
Platelet count decreased 9 (18.4) 2 (4.1) 1 (2.0) 12 (24.5) 3 (6.1) 0 
Decreased appetite 13 (26.5) 2 (4.1) 0 10 (20.4) 0 0 
Vomiting 10 (20.4) 0 0 15 (30.6) 0 0 
Weight decreased 9 (18.4) 1 (2.0) 0 15 (30.6) 0 0 
Diarrhoea 8 (16.3) 1 (2.0) 0 10 (20.4) 1 (2.0) 0 
Arthralgia 8 (16.3) 1 (2.0) 0 5 (10.2) 4 (8.2) 0 
Hypertension 9 (18.4) 1 (2.0) 0 4 (8.2) 4 (8.2) 0 
Neutrophil count decreased 9 (18.4) 2 (4.1) 0 4 (8.2) 2 (4.1) 1 (2.0) 
Dyspnoea 5 (10.2) 1 (2.0) 0 10 (20.4) 1 (2.0) 0 
Abdominal pain 4 (8.2) 0 0 6 (12.2) 5 (10.2) 1 (2.0) 
Blood creatinine increased 9 (18.4) 0 0 6 (12.2) 0 0 
Oedema peripheral 6 (12.2) 0 0 8 (16.3) 1 (2.0) 0 
Urinary tract infection 3 (6.1) 3 (6.1) 0 6 (12.2) 3 (6.1) 0 
Constipation 7 (14.3) 0 0 7 (14.3) 0 0 
Cough 3 (6.1) 0 0 9 (18.4) 0 0 
Musculoskeletal chest pain 3 (6.1) 0 0 9 (18.4) 0 0 
Musculoskeletal pain 5 (10.2) 1 (2.0) 0 5 (10.2) 1 (2.0) 0 
Hypokalaemia 3 (6.1) 0 0 8 (16.3) 0 0 
Muscular weakness 4 (8.2) 0 0 5 (10.2) 2 (4.1) 0 
WBC count decreased 4 (8.2) 0 0 6 (12.2) 1 (2.0) 0 
AST increased 3 (6.1) 0 1 (2.0) 4 (8.2) 1 (2.0) 0 
ALP increased 3 (6.1) 0 0 5 (10.2) 1 (2.0) 0 
Dysgeusia 6 (12.2) 0 0 3 (6.1) 0 0 
Haematuria 5 (10.2) 0 0 2 (4.1) 2 (4.1) 0 
Influenza like illness 3 (6.1) 0 0 6 (12.2) 0 0 
Muscle spasms 3 (6.1) 0 0 6 (12.2) 0 0 
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  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
GGT increased 3 (6.1) 0 0 2 (4.1) 2 (4.1) 1 (2.0) 
Lower resp. tract infection 4 (8.2) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Lymphocyte count decreased 2 (4.1) 1 (2.0) 0 3 (6.1) 2 (4.1) 0 
Pyrexia 4 (8.2) 2 (4.1) 0 2 (4.1) 0 0 
ALT increased 2 (4.1) 0 0 3 (6.1) 2 (4.1) 0 
Groin pain 3 (6.1) 0 0 2 (4.1) 2 (4.1) 0 
Dizziness 2 (4.1) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Spinal cord compression 0 1 (2.0) 0 0 5 (10.2) 0 
Blood bilirubin increased 1 (2.0) 0 0 3 (6.1) 0 1 (2.0) 
Cellulitis 2 (4.1) 0 0 2 (4.1) 1 (2.0) 0 
Pain 1 (2.0) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Hydronephrosis 1 (2.0) 2 (4.1) 0 0 1 (2.0) 0 
Hyponatraemia 0 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Myocardial infarction 0 1 (2.0) 2 (4.1)* 0 1 (2.0) 0 
Acute kidney injury 1 (2.0) 0 1 (2.0) 1 (2.0) 0 0 
Hyperkalaemia 0 1 (2.0) 0 2 (4.1) 0 0 
Rectal haemorrhage 0 1 (2.0) 0 1 (2.0) 1 (2.0) 0 
Amylase increased 0 0 0 1 (2.0) 1 (2.0) 0 
Atrial fibrillation 0 0 0 1 (2.0) 1 (2.0) 0 
Circulatory collapse 0 2 (4.1) 0 0 0 0 
Confusional state 1 (2.0) 1 (2.0) 0 0 0 0 
Femoral neck fracture 0 1 (2.0) 0 1 (2.0) 0 0 
Femur fracture 0 0 0 0 2 (4.1) 0 
Mobility decreased 1 (2.0) 0 0 0 1 (2.0) 0 
Pneumonia 0 0 0 0 2 (4.1) 0 
Presyncope 1 (2.0) 0 0 0 1 (2.0) 0 
Pulmonary embolism 0 1 (2.0) 0 0 1 (2.0) 0 
Respiratory tract infection 1 (2.0) 1 (2.0) 0 0 0 0 
Abdominal infection 0 1 (2.0) 0 0 0 0 
Acute myeloid leukaemia 0 0 1 (2.0) 0 0 0 
Arthritis bacterial 0 1 (2.0) 0 0 0 0 
Bronchitis 0 1 (2.0) 0 0 0 0 
Cauda equina syndrome 0 0 0 0 1 (2.0) 0 
Embolism 0 0 0 0 1 (2.0) 0 
Enterocolitis infectious 0 0 0 0 1 (2.0) 0 
Febrile neutropenia 0 0 0 0 1 (2.0) 0 
Hip fracture 0 1 (2.0) 0 0 0 0 
Intestinal obstruction 0 0 0 0 1 (2.0) 0 
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  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
Jaundice 0 0 0 0 1 (2.0) 0 
Neutropenic sepsis 0 0 0 0 1 (2.0) 0 
Pyelonephritis 0 0 0 0 1 (2.0) 0 
Radiculopathy 0 0 0 0 1 (2.0) 0 
Renal colic 0 1 (2.0) 0 0 0 0 
Sepsis 0 0 0 0 0 1 (2.0) 
Ureteric obstruction 0 1 (2.0) 0 0 0 0 
Urosepsis 0 1 (2.0) 0 0 0 0 
Vascular pseudoaneurysm 0 0 1 (2.0) 0 0 0 
Vision blurred 0 1 (2.0) 0 0 0 0 
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RESEARCH IN CONTEXT 
Evidence before this study 
Trials for advanced prostate cancer have rarely pursued molecular stratification, and 
none of the drugs approved up to date for metastatic prostate cancer care have a 
validated companion biomarker. Before starting this study, several genomic landscape 
studies were published describing an enrichment for aberrations in DNA repair genes in 
metastatic prostate cancers (studies identified in Pubmed, searching for “prostate 
cancer”, “genomics”, “biopsy”, between 2010 and 2015). Preclinical and clinical studies 
identified in Pubmed (search for “cancer”, “PARP” and “BRCA” or “DNA repair” 
between 2005 and 2019) have established a correlation between different DNA repair 
defects and sensitivity to PARP inhibition in different tumour types, leading to drug 
approvals in ovarian and breast cancer. In the TOPARP-A trial, we identified an 
association between somatic alterations in DNA repair genes and antitumour activity of 
olaparib in 49 patients with metastatic prostate cancer. Other clinical trials of PARP 
inhibitors in prostate cancer were identified using ClinicalTrials.gov website, searching 
for “prostate cancer” and “PARP”. 
 
Added value of this study 
To our knowledge, this is the first ever prospective clinical trial for a genomically-
defined population of metastatic prostate cancers. TOPARP-B aims to clinically qualify, 
for the first time, a predictive biomarker for treating metastatic prostate cancers. 
TOPARP-B also assessed different doses of olaparib, and correlated different genomic 
aberrations and antitumour activity. This study has confirmed the antitumour activity of 
olaparib against metastatic prostate cancer with defective DNA repair, secondary to 
either germline or somatic gene inactivation. 
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Implications of all the available evidence 
Randomised phase III trials for DNA repair defective prostate cancers are now ongoing 
based on these data. Our results, if confirmed in registration studies, would support 
implementing tumour genomic testing in clinical practice for treatment stratification in 
advanced prostate cancer.  
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ABSTRACT 
Background  
Metastatic castration-resistant prostate cancer (mCRPC) is enriched in DNA damage repair 
(DDR) gene aberrations (DDRga). The TOPARP-B trial aims to prospectively validate the 
association between DDRga and response to olaparib in mCRPC.  
 
Methods 
In this randomised “pick-the-winner” phase 2 study we recruited participants from 17 UK 
hospitals. Men with progressing mCRPC following ≥1 taxane chemotherapy regimens and 
ECOG performance status ≤2 had tumour biopsy targeted sequencing. Patients with DDRga 
were randomised 1:1, by computer-generated minimisation method balancing for screening 
circulating tumour cell (CTC) count, to 400mg or 300mg olaparib twice daily, given 
continuously in 4-week cycles until disease progression or unacceptable toxicity. Neither 
participants nor investigators were blinded to dose allocation. The primary endpoint response 
rate (RR) was defined as a composite of radiological objective response (as assessed by 
Response Evaluation Criteria in Solid Tumors 1.1), prostate specific antigen decline of ≥50% 
(PSA50) from baseline and/or CTC count conversion (≥5 at baseline to <5/7.5ml blood). 
Confirmed response in consecutive assessment after >4 weeks was required for each 
component. Primary analysis was performed in the evaluable population. The trial aimed to 
exclude ≤30% confirmed RR in either arm.  ClinicalTrials.gov, NCT01682772; recruitment 
completed and follow-up ongoing. 
 
Findings 
Overall, 711 patients consented for targeted screening between April 1 2015 and August 30 
2018; 161 had DDRga; 98 were randomised and treated (49:49), with 92 evaluable for the 
 4 
primary endpoint (46:46). Median follow-up time was 24.8 months (Q1-Q3 16.7 to 35.9 
months). Confirmed composite RRs were 54% (25/46, 95%CI 39-69%, meeting the threshold 
for primary endpoint) in the 400mg cohort, and 39% (18/46, 95%CI 25-55%) in the 300mg 
cohort. For each component, response rates were: radiological 400mg 8/33 (24%) vs 300mg 
6/37 (16%); PSA50 400mg 17/46 (37%) vs 300mg 13/43 (30%); CTC count conversion 
400mg 15/28 (54%), 300mg 13/27 (48%).  The most common grade 3-4 adverse event in 
both cohorts was anaemia (300mg 15/46 [30.6%]; 400mg 18/46 [36.7%]). 19 serious adverse 
reactions in 10 patients were reported. One possibly treatment-related death (myocardial 
infarction) occurred after 11 days of  treatment (300mg cohort). 
 
Interpretation  
Olaparib has antitumour activity against mCRPC with DDRga, especially tumours with 
BRCA1/2 and PALB2 alterations, supporting implementation of mCRPC genomic 
stratification in clinical practice.  
 
Funding 
Cancer Research UK, AstraZeneca, Prostate Cancer UK, Prostate Cancer Foundation, 
Experimental Cancer Medicine Centres Network, and National Institute for Health Research 
Biomedical Research Centres.  
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INTRODUCTION 
Molecular stratification for treatment is not currently standard-of-care for metastatic 
prostate cancers despite the elucidation of marked inter-patient genomic heterogeneity. 
Most therapeutic strategies for advanced prostate cancers target androgen receptor 
signalling; taxane-based chemotherapies and radiopharmaceuticals are also approved
1
. 
While these agents have improved outcomes in the last decade, metastatic prostate 
cancer remains invariably fatal and new therapeutic molecularly-stratified strategies are 
urgently needed. Genomic studies of metastatic prostate cancer have identified multiple 
potentially actionable recurrent genomic aberrations
2-4
, including loss-of-function 
alterations in DNA repair genes in 20-25% of cases, including defects in homologous 
recombination mediated repair genes 
3
. Among these, germline or somatic alterations in 
BRCA2 are the commonest, accounting for 6-12% of cases across studies. These data 
underpin the evaluation of poly-(adenosine diphosphate [ADP]–ribose) polymerase 
(PARP) inhibitors in this disease
5,6
. 
 
Olaparib is an orally-bioavailable inhibitor of the catalytic activity of PARP1 and 
PARP2, which have key roles in DNA defect repair (DDR). Olaparib is approved for 
the treatment of advanced ovarian and breast cancers associated with germline BRCA1 
or BRCA2 mutations
7
. It is also approved as maintenance therapy after response to 
platinum-based chemotherapy for ovarian cancer, indicating benefit from PARP 
inhibition beyond tumours with BRCA1/2 mutations 
8,9
. Further, olaparib has antitumour 
activity in in-vitro and in-vivo models defective in other DDR proteins including 
PALB2, ATM, FANCD2, RAD51, RAD54 and others, although the magnitude of 
preclinical sensitization varies between proteins, with BRCA2 loss being arguably the 
most potent sensitizing event
10,11
.   
 6 
 
To evaluate the antitumour activity of olaparib against metastatic castration resistant 
prostate cancer (mCRPC), we designed TOPARP, an adaptive program of serial phase 2 
clinical trials aimed at identifying predictive biomarkers for response to PARP 
inhibition in mCRPC. In the first trial, TOPARP-A, we identified an association 
between putatively deleterious DDRga and response to olaparib in 49 molecularly 
unselected patients
12
. We present here the results of TOPARP-B, designed to validate 
the observed antitumour activity in mCRPC patients with DDRga. Two different dose 
levels of olaparib were explored: 400mgs twice daily (BID) as used in TOPARP-A, and 
300mg BID, the approved dose for ovarian and breast cancers
13
.  
 
  
 7 
METHODS 
Study design and participants 
TOPARP-B is a multi-centre, open-label, investigator-initiated randomised phase 2 trial 
where patients with tumours known to have deleterious DDRga that may sensitize to 
PARP inhibition were randomised to receive olaparib at either 300 mg BID or 400 mg 
BID tablets.  Patients were recruited from 17 UK hospitals (appendix p 2) and 
molecularly pre-selected based on targeted next-generation sequencing (NGS) of 
primary or metastatic prostate cancer biopsies. Eligible patients were men aged 18 years 
or older, with histologically confirmed prostate adenocarcinoma that had developed 
metastasis and castration-resistance, whose tumours had a putatively pathogenic 
mutation or homozygous deletion in a DDR gene that could be associated with 
sensitivity to PARP inhibition. Patients were required to have previously received at 
least one but no more than two taxane-based chemotherapy regimens, regardless of 
prior exposure to novel hormonal agents. Other inclusion criteria included: documented 
prostate cancer progression at trial entry either by prostate-specific antigen (PSA, 
according to the PCWG2 criteria
14
), and/or radiologically (according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1
15
 or by bone scan as per 
PCWG2 criteria); castrate testosterone levels of <50 ng/dL; Eastern Cooperative 
Oncology Group (ECOG) Performance Status ≤2; adequate organ function (including 
haemoglobin ≥9g/dL after protocol amendment in March 15, 2018 (previously 
≥10g/dL), platelets ≥100x109/L, serum creatinine ≤1.5 x times above institutional range 
of normal values and albumin >25 g/dl). Patients previously treated with PARP 
inhibitors, platinum, cyclophosphamide or mitoxantrone were not eligible, as well as 
patients with known symptomatic brain metastasis or untreated cord compressions. 
Baseline count for circulating tumour cells (CTC) (CellSearch® system [Menarini 
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Silicon Biosystems, Inc, Bryn Athin, USA]) had to be >5 cells/7.5 ml blood except for 
patients with radiologically measurable target lesions ≥2cm in diameter on the baseline 
CT scan. A full list of inclusion/exclusion criteria, as well as the complete study 
protocol, is available in the appendix (pp 3-4, 20-148). 
 
Patients provided written informed consent before enrolment, both for the NGS pre-
screening and treatment stages. The study was approved by the London, Surrey Borders, 
Research Ethics Committee (REC reference 11/LO/2019), and co-sponsored by The 
Royal Marsden Hospital and The Institute of Cancer Research (ICR), London, UK. The 
trial was conducted in accordance with the principles of good clinical practice and 
overseen by Independent Data Monitoring (IDMC) and Trial Steering (TSC) 
committees. A Trial Management Group was responsible for the day-to-day running of 
the trial. The Clinical Trials and Statistics Unit at the ICR (ICR-CTSU) had overall 
responsibility for trial coordination, monitoring and analysis.  
 
Randomisation and masking 
Patients were registered into the trial for NGS pre-screening, and subsequently, eligible 
patients were randomly allocated (1:1) to olaparib 300mg BID or olaparib 400mg BID. 
Randomisation was done centrally by the ICR-CTSU via telephone. The allocation 
sequence was generated centrally by computer-generated minimisation algorithm 
derived by ICR-CTSU, with CTC count at screening (≥5 or < 5 cells/7.5 ml blood) as a 
balancing factor. ICR-CTSU staff involved in the randomisation service were not 
involved in the clinical running of the trial or data collection. Neither participants nor 
clinicians were blinded to dose allocation.   
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Procedures 
In the pre-screening part of the study, primary and/or metastatic prostate cancer samples 
were acquired to identify tumours with putatively deleterious DDRga by targeted NGS 
at the Cancer Biomarkers Laboratory at The ICR. DNA was extracted from formalin-
fixed and paraffin embedded (FFPE) tumour blocks using the FFPE Tissue DNA kit 
(Qiagen). Samples that passed quality control criteria were used for library preparation 
using a customized panel (Generead DNAseq Mix-n-Match Panel v2; Qiagen) covering 
113 genes; libraries were read using a MiSeq Sequencer (Illumina). Expanded details on 
sample processing, quality check, and bioinformatics pipelines, as well as the panel 
design, are available in the appendix (pp 5-7).
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 Patients previously known to have 
germline aberrations were eligible only upon confirmatory tumour NGS testing.  
 
All patients received olaparib at either of the allocated dose levels (300 and 400mgs 
BID) continuously in 4-week cycles until evidence of radiographic progression, 
unacceptable toxicity or patient decision to discontinue. Discontinuation due to clinical 
progression was based on treating clinician decision; discontinuation based solely on a 
rising PSA in the absence of radiographic or clinical progression was discouraged. 
Patients treated with 300mg BID were allowed to increase the olaparib dose to 400mg 
BID at confirmation of disease progression, providing this was considered clinically 
indicated by the treating physician and the patient had not previously required a dose 
reduction for management of toxicity. 
 
Clinical assessments, including review of adverse events, performance status, physical 
examination and routine blood tests (haematology and biochemistry) took place after 2-
weeks of starting treatment, and then at the start of every new 4-weekly cycle. 
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Radiological assessments (CT scan, bone scan) were performed every 12-weeks. CTC 
counts were measured every cycle for the first 12-weeks, and thereafter every 12-weeks. 
CTC counts were centrally analysed, and were not made available to the treating 
physician. PSA assessment was collected every cycle if available, and every 12-weeks 
as a minimum. Blood samples for correlative biomarker studies were taken on a 4-
weekly basis. Repeated tumour biopsies were optional, and pursued when feasible at 
baseline, after 1-4 weeks on therapy and at the time of progression. Adverse events 
were assessed using the National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) version 4. Guidelines on drug interruptions or dose 
reductions for haematological and non-haematological toxicities were implemented as 
outlined in the protocol (appendix pp 20-148). Up to 42-days of temporary interruption 
of treatment was allowed prior to mandating permanent discontinuation. 
 
Outcomes 
The primary endpoint was confirmed tumour response, defined as a composite of: 
objective response by RECIST 1.1 (with PCWG2 caveats) and/or PSA decline of ≥50% 
from baseline and/or conversion of CTC count from ≥5 cells/7.5 ml blood at baseline to 
<5 cells/7.5 ml
17
. To be considered a response for the primary analysis, at least one of 
these three tumour response components, confirmed in a second consecutive assessment 
obtained four or more weeks later, was required.  
 
Protocol-defined secondary endpoints were: radiographic progression-free survival 
(rPFS), defined as time from randomisation to first evidence of radiographic 
progression (by RECIST 1.1 or bone scan as per PCWG2 criteria) or death; time to 
radiographic progression, defined as time from randomisation to first evidence of 
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radiographic progression; progression-free survival, defined as time from randomisation 
until radiographic progression, unequivocal clinical progression or death; overall 
survival (OS), defined as time from randomisation to death by any cause; time to PSA 
progression, defined as a confirmed ≥25% increase and absolute increase of ≥ 2 ng/mL 
in PSA above the nadir (PCWG2); duration of PSA response, defined as the time from 
the first documented ≥50% decline to PSA progression; best percentage change in PSA 
from baseline whilst on treatment, percentage change in PSA from baseline at 12 weeks 
(or earlier if discontinued therapy); proportion of patients with CTC conversion; and the 
safety and tolerability profile of olaparib in men with mCRPC. Pre-specified 
exploratory endpoints included the evaluation of response in patients who escalated 
dose to 400mg BID after progression on 300mg BID. A pharmacokinetics sub-study 
was planned but due to challenges in recruitment it was closed prematurely with no 
analyses pursued. 
 
Statistical Analysis 
Patients were randomised to either 400mg or 300mg BID of olaparib, under a “pick-the-
winner” design18. Each dose cohort was assessed independently for the primary 
endpoint. The sample size to demonstrate the minimum desired antitumour activity was 
based on a one-stage A’Hern design, with RR≤30% for the null hypothesis, and 
RR>50% for the alternative hypothesis (one-sided alpha level 0.05; beta level 0.15). If 
at least 19/44 evaluable patients in a dose cohort responded (43%), then the dose cohort 
would be considered successful. If the 400 mg BID dose cohort was deemed successful, 
the biomarker identified in TOPARP-A, where all patients received 400mg BID, would 
be considered validated. In the event of both dose cohorts being successful, the pick-
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the-winner selection strategy would include consideration of secondary endpoints. No 
formal interim analyses were planned. 
 
For the primary endpoint, the evaluable population was defined as all randomised 
patients who met all of the inclusion and exclusion criteria, and commenced trial 
treatment, unless they discontinued treatment prior to 12-weeks for reasons that were 
not drug or disease related. Sensitivity analyses of the primary endpoint on the ITT (all 
randomised patients) and per protocol (all evaluable patients who received at least one 
cycle of olaparib, and had no major protocol violations) populations were conducted. A 
post-hoc sensitivity analysis on patients with CTC count ≥5 cells/7.5ml blood at 
baseline was performed for comparison with TOPARP-A results. All other efficacy 
analyses were performed on the ITT population.  
 
Analysis of the primary endpoint was triggered when all patients had completed at least 
6-months of treatment (in the absence of prior discontinuation). Evaluable patients who 
discontinued prior to 12-weeks due to progression or toxicity and had no follow-up 
assessments for the primary endpoint were considered non-responders. Response rates 
are presented along with exact two-sided 95% confidence intervals. Local radiological 
response assessment was used for the primary endpoint definition; all RECIST 1.1 
responses were confirmed by central review. Percentage changes from baseline in PSA 
levels and sum of target lesions, are represented in waterfall plots. Time-to-event 
endpoints are summarised by Kaplan-Meier curves, and median times estimated with 
95% confidence intervals. For rPFS and PFS, patients alive and without progression 
were censored at the last scheduled disease assessment on study. For time to 
radiographic progression, patients who did not progress radiologically were censored at 
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the last scheduled disease assessment on study or date of death, whichever occurred 
earlier. Patients alive at the end of follow-up were censored for the analysis of OS. 
Landmark analyses were used to explore the association between CTC conversion at 8- 
and 12-weeks and rPFS and OS.  
 
Subgroup analysis based on different genes of interest were pre-planned for efficacy 
endpoints. Five non-mutually exclusive subgroups were predefined: patients with 
alterations in BRCA1/BRCA2; ATM, CDK12, PALB2, and, lastly, patients with 
alterations in any other gene related to DDR or associated to PARPi sensitivity. Patients 
that had more than one DDRga were included in the analysis of all relevant subgroups.  
 
Toxicity was analysed on all patients who received at least one dose of olaparib, and 
worst grades of adverse events (AEs) during treatment for each dose cohort are 
reported. Serious AEs and deaths observed within 30-days of the last dose of study 
treatment were summarised by dose cohort, as well as the exposure to study drug and 
reasons for discontinuation, dose modification or interruption and /or treatment delay.  
 
The trial was not powered for head-to-head direct comparisons of the two dose-cohorts, 
so tests to compare them are considered hypothesis-generating (e.g. Chi-square test to 
compare response rates, and log-rank test to compare Kaplan-Meier curves). Further 
exploratory analyses are planned in the protocol and will be reported elsewhere. 
Statistical analyses were conducted with the use of Stata software (version 15), on a 
snapshot of the data taken on July 5, 2019. The Statistical Analysis Plan is available in 
the appendix (pp 149-177). 
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This study was registered with ClinicalTrials.gov (NCT01682772) and on the European 
Clinical Trials database (EudraCT 2011-000601-49). 
 
Role of the funding sources 
The funders had no role in the study design, data collection, analysis and interpretation, 
or in the preparation of the report. The corresponding author had full access to all data 
in the study and final responsibility for the decision to submit for publication.  
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RESULTS 
Between April 1 2015 and August 30 2018, 711 patients consented for NGS pre-
screening (Figure 1A). For 30 (4.2%) patients, no samples were made available for 
testing. From 681 patients with at least one sample available, 779 tumour samples were 
analysed (637 [82%] primary tumour samples, 142 [18%] post-castration resistance 
metastatic biopsies). For 89 (13%) patients, biomarker determination was not possible 
due to the sample, or the sequencing data, not fulfilling quality control parameters.  
 
Of the 592 patients with evaluable tissue samples, 161 (27%) had DDRga based on 
NGS, while 431 (73%) did not. An oncoprint summarizing all alterations detected in the 
pre-screening phase of the study is presented in the appendix (p 14). The commonest 
detected DDRga were mutations or homozygous deletions in BRCA2 (44/592, 7.4%), 
ATM (40/592, 6.8%) and CDK12 (33/592, 5.6%). 
 
Ninety-eight DDRga patients were randomised and treated in the two dose-level cohorts 
(49 patients in each cohort). At the time of data snapshot, two patients remained on 
olaparib treatment. More participants were recruited than originally planned, at the 
recommendation of the IDMC, to account for six participants (three in each cohort) who 
were deemed not evaluable (determined ineligible post-randomisation) for the primary 
endpoint analyses. Median follow-up was 24.8 months (Q1-Q3 16.7 to 35.9 months). 
 
Patients baseline characteristics are shown in Table 1; all had previously received 
docetaxel, and 88 (90%) had also been treated with abiraterone acetate (46) and/or 
enzalutamide (56) prior to study entry. The commonest sites for metastases at trial entry 
were bone (82; 84%) and lymph nodes (66; 67%), with measurable soft-tissue disease 
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being present in 75 (77%) patients. The distribution of gene subgroups was largely 
similar between the two dose cohorts, except for CDK12 alterations which was 
imbalanced (31% 300mg vs 12% 400mg). The composition of pre-specified gene 
subgroups per cohort is shown in Figure 1B. Baseline features for each gene subgroup 
are summarised in the appendix (p 8).  
 
For the 92 patients in the evaluable population for the primary endpoint, 70 (76%), 89 
(97%) and 55 (60%) were evaluable for the RECIST 1.1, PSA, and CTC conversion 
components of the response definition respectively. The confirmed composite response 
rates were 25/46 (54%; 95%CI 39-69%) in the 400mg cohort, and 18/46 (39%; 95%CI 
25-55%) in the 300mg cohort (p-value p=0.14) (Table 2).  For each component of the 
primary endpoint, response rates were: radiological response 400mg 8/33 (24%) vs 
300mg 6/37 (16%); PSA response 400mg 17/46 (37%) vs 300mg 13/43 (30%).; CTC 
count conversion 400mg 15/28 (54%), 300mg 13/27 (48%). Based on the first 44 
evaluable patients included in each cohort (as planned initially), there were 25/44 
confirmed responses in the 400mg BID cohort, and 18/44 confirmed responses in the 
300mg BID cohort; hence, the predefined criteria for success was met for 400mg BID 
but not for 300mg BID.  
 
When considering only the 55 evaluable patients with >5 CTC/7.5ml blood at baseline, 
confirmed composite response rates were 61% (17/28, 95%CI 41-79%) in the 400mg 
cohort, and 48% (13/27, 95%CI 29-68%) in the 300mg cohort (see appendix p 9 for 
each individual component). In keeping with previous reports
17,19
, CTC conversions 
post-treatment significantly associated with longer rPFS and OS in landmark analyses 
(appendix p 15). 
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Maximum change from baseline in PSA and sum of target lesions while on allocated 
treatment are presented in Figure 2A and 2B. Overall, 45 ITT patients at 400mg (92%) 
and 46 ITT patients at 300mg (94%) had radiographic progression or death; median 
rPFS was 5.5 months (95%CI 4.4-8.3) in the 400mg cohort, and 5.6 months (95%CI 
3.7-7.7) in the cohort (Figure 2C). At the time of analyses, 39 400mg (80%) and 38 
300mg (78%) patients were deceased, with a median overall survival of 14.3 months 
(95%CI 9.7-18.9) in the 400mg cohort and 10.1 months (95%CI 9-17.7) in the 300mg 
cohort. Further results on the secondary endpoints are summarised in the appendix (pp 
16-18). Time on treatment for each patient is represented in Figure 2D. A summary of 
treatment dose reductions, interruptions and discontinuations by dose cohort is 
presented in the appendix (p 10). 
 
Dose escalation from 300 mg to 400 mg was pursued in 11 patients; at the time of the 
data snapshot, 10 had discontinued treatment: two due to adverse events and eight for 
disease progression. These 11 patients were on treatment with 400mg for a median of 
7.8 weeks (Q1-Q3: 3.7-10.4).  None of these patients achieved a response after dose-
escalation.  
 
The confirmed composite response rates, and by individual components, for each of the 
predefined gene subgroups are shown in Table 2. Further analysis of secondary 
endpoints per gene subgroup can be found in Figure 3 and appendix (pp 11, 19). 
 
The BRCA1/BRCA2 subgroup had the highest response rate (25/30, 83%, 95%CI 65-
94%), and the longest median rPFS of all DDRga subgroups (8.3 months, 95%CI 5.5-
 18 
13.0). The median OS for the BRCA1/BRCA2 subgroup was 17.7 months (95%CI 9.9-
22.2). Of the 32 patients included in this BRCA1/BRCA2 subgroup, 13 had germline 
mutations in BRCA2, six somatic mutations in BRCA2, 11 homozygous deletions in 
BRCA2, and the remaining two cases had mutations in BRCA1 (one germline, one 
somatic). Ten patients in the BRCA1/BRCA2 subgroup (five allocated to 400mg BID, 
five allocated to 300mg BID) remained on treatment for over one year.  
 
Twenty-one patients with suspected deleterious ATM aberrations were treated (one 
patient with homozygous deletion; the rest with germline or somatic mutations that are 
predicted to either result in truncation or missense mutations affecting the kinase 
domain). The composite response rate in patients with ATM aberrations was 37% (7/19; 
95%CI 16-62%), with only 2 of those were RECIST/PSA responses (appendix p 12).  
Median rPFS and OS for the ATM altered subgroup were 5.8 months (95%CI 4.4-10.9) 
and 16.6 months (95%CI 8.9-24.2), respectively.  
 
No confirmed PSA or RECIST responses were observed in the CDK12 mutated 
subgroup, although 5/12 evaluable patients achieved a CTC conversion (including one 
with concomitant BRCA1/2 alteration) (appendix pp 13). Median rPFS was 2.9 months 
(95% CI 2.6-7.5) and median OS was 9.5 months (95%CI 8.2-10.1). 
 
Conversely, 4/7 (57%; 95%CI 18-90%) patients with PALB2 mutations responded to 
treatment, all four had confirmed PSA responses, and two of them also had confirmed 
radiological responses. The median rPFS and OS in this subgroup were 5.3 months and 
13.9 months respectively (95% CI could not be estimated due to small number of 
patients/events). 
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Lastly, 21 patients were evaluated as part of the subgroup with “other gene alterations”. 
The composite response rate in this subgroup was 20% (4/20 patients, 95%CI 6-44), 
with median rPFS of 2.8 months (95%CI 2.6-4.3) and median OS of 7.7 months 
(95%CI 4.3-19.1). PSA responses were seen in one patient whose tumour had a somatic 
nonsense mutation in FANCA and one patient with a CHEK2 mutation. 
 
The safety population included all 98 patients treated. The tolerability profile was in 
line with what has been previously reported for olaparib and other PARP inhibitors
20-22
 
(Table 3). Anaemia was the most common treatment-emergent adverse event (69%), 
with 34% experiencing G3-4 anaemia. Fatigue was also common (54.1%; 7% grade 3-
4). Grade 3-4 gastrointestinal toxicities were rare (1% nausea, 2% decreased appetite, 
2% diarrhoea). Anaemia was the commonest AE leading to dose reductions; 18 (37%) 
patients in the 400mg cohort, and six (12%) in the 300mg cohort, required at least one 
dose reduction (appendix p 10). Eight patients achieving a response while on 400mg, 
continued to respond for more than 6-months after dose reduction to 300mg or lower. 
Overall, 18/98 (19%) patients were permanently discontinued from olaparib treatment 
due to AE.  
 
A total of 107 serious adverse events were reported in 49 (50%) patients, with 19 
serious adverse reactions (SAR, possibly related to study drug, 11 in 300mg, 8 in 
400mg) in 13 patients. The commonest SAR was anaemia (6 in 300mg, 5 in 400mg). 
Four SAR were considered suspected unexpected (SUSAR, two in each dose cohort 
group), including a patient diagnosed with myelodysplasia after 6.5 months of 300mg 
olaparib. This patient developed acute myeloid leukaemia after olaparib discontinuation. 
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One 300mg patient (2%) died due to a myocardial infarction, assessed as possibly drug 
related, after 11-days of treatment. All other deaths were unrelated to treatment.   
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DISCUSSION 
TOPARP-B has confirmed the antitumour activity of olaparib against metastatic 
prostate cancers (mPC) with specific DDRga. The number of composite responses 
observed in the 400mg BID cohort met the predefined criteria for success, validating the 
biomarker identified in TOPARP-A
12
. Overall, the data suggest that both drug dose and 
the specific DDR gene aberration type may matter to antitumour activity since the 
composite response rate at the 300mg BID was lower and did not reach predefined 
criteria for success. The antitumour activity observed varied considerably for different 
DDRga, with the most impressive antitumour activity seen in the BRCA1/BRCA2-
altered subgroup.  
 
Despite randomisation, there was an imbalance in CDK12 aberrations between cohorts, 
with an enrichment for these in the 300mg cohort. This may explain, at least in part, the 
inferior composite response rate in the 300mg cohort
4,23
. The rationale to explore these 
two dose levels originated from prior clinical observations indicating a dose-response 
relationship for olaparib between 100mg BID and 400mg BID, although this dose 
increase is associated with increased toxicity 
24,25
. In keeping with this, 37% patients at 
400mg BID had to dose reduce to 300mg BID, most commonly due to anaemia; all 
these data would need to be considered when assessing the optimal dose of olaparib for 
prostate cancer care.  
 
These results support the implementation of routine genomic testing of metastatic 
prostate cancer, to detect DNA repair defects for PARP inhibition. In previous studies, 
we reported an enrichment for germline inherited mutations in DDR genes in this 
mCRPC population
26
, which has led to a recommendation of broad germline NGS 
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testing for all men suffering from mPC per NCCN guidelines. The antitumour activity 
demonstrated herein for olaparib in mCRPC patients with both germline and somatic 
aberrations of BRCA2 now supports the implementation of NGS testing of tumour 
samples.  
 
Antitumour activity was also observed in other DDRga subgroups. Responses in 
tumours with PALB2 mutations were frequent (4/7 patients), although the low 
prevalence of these mutations means that further data are required to confirm these 
findings. Clinical qualification of low-prevalence biomarkers is challenging in the 
pursuit of precision medicine approaches; the validation of genomic signatures
23,27
 or 
functional biomarkers
28
 that identify tumours with defective homologous-
recombination, regardless of the mutated gene of origin, could help move the field 
forward, but such assays have not been yet validated in prostate cancer. 
 
Conversely, germline and somatic ATM aberrations are common in mPC; ATM 
functions as a cell cycle checkpoint, preventing cell cycle progression in the presence of 
DNA damage rather than directly mediating repair unlike BRCA2 and PALB2. In the 
TOPARP-A trial, 5 patients had ATM aberrations in tumour biopsies: 2 of these had a 
PSA response, and a further 2 achieved a CTC conversion. Preliminary reports suggest 
that rucaparib, another PARP inhibitor, resulted in few PSA falls in patients with ATM 
aberrations
29
. In TOPARP-B, we treated 21 patients with suspected deleterious ATM 
aberrations; two of them achieved a RECIST/PSA response, and several others had 
CTC counts conversions following therapy. CTC count falls seen in this sub-group 
associated with longer duration on trial, tumour shrinkage by RECIST and PSA falls 
(appendix p 12), as was the case for the overall TOPARP-B population, with CTC 
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conversions robustly associating with longer rPFS and OS. Overall, these data indicate 
that the antitumour activity of olaparib in ATM loss mCRPC is less than that for BRCA 
altered tumours; nevertheless, a subset of these patients with ATM altered mCRPC 
appear to derive benefit. Detection of ATM alterations alone may, however, be 
insufficient to identify these sensitive tumours. Further studies, as well as the study of 
rational drug combinations, are now needed to elucidate how to best evaluate and treat 
mCRPC with ATM alterations. Ongoing exploratory analysis from this trial will look 
into further characterization of exceptional responses within each gene-defined 
subgroup to optimize patient stratification.  
 
We do acknowledge limitations to this study. While the utilization of targeted NGS 
facilitates the clinical implementation of patient stratification, this may be insufficient to 
capture more complex aberrations resulting in PARPi sensitivity. Moreover, as all 
patients in this study had DDRga and received olaparib, we are not able to fully 
differentiate the predictive value versus the prognostic impact on of the survival data. 
Randomised trials including biomarker-positive and biomarker-negative patients are 
more able to clinically qualify a putative predictive biomarker.  
 
Nonetheless, these TOPARP results have overall driven the design and conduct of 
multiple registration trials of PARP inhibitors in mCRPC that are likely to guide the 
clinical use of PARP inhibitors in mPC in the future. Most of these studies aim to 
validate PARP inhibition as a precision medicine strategy for prostate cancers with 
DDRga; other studies, in parallel, explore the addition of PARP inhibitors to standard-
of-care AR targeting agents, based on results from a phase II clinical trial which has 
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been reported to indicate that a broader target population may benefit from these 
agents
30
. 
 
In conclusion, these TOPARP-B data have confirmed the antitumour activity of 
olaparib against mPC with certain DDRga. The high response rates observed in patients 
with mCRPC with germline or somatic BRCA1/2 aberrations, and the durability of 
many of these responses, support the use of olaparib in this sub-population. The 
antitumour activity observed against tumours with ATM, PALB2, FANCA or CHEK2 
aberrations suggest that PARPi may have a role as a single agent or in rational 
combinations against these other mPC subtypes, although further data are needed to 
precisely assess the clinical relevance of each of these different DDRga in prostate 
cancer. 
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Figure legends 
Figure 1. (A) CONSORT Flow diagram of patient disposition in the TOPARP-B trial 
(B) Oncoprint of mutations and homozygous deletions in DDR genes that led to trial 
inclusion for the IIT population (n=98)**.  
DDRga= Defective DNA Repair Gene aberration  
* Non-mutually exclusive subgroups: One patient treated at 300mgs BID had BRCA1/2, 
CDK12 & ‘Other mutations’ (300mg); two further 300 mg patients had both PALB2 & 
‘Other mutations’. 
** The BRCA2 K3226* variant was not considered sufficient for patients to be 
considered eligible; however, one patient with a BRCA2 K3226* variant was included 
due to evidence of concomitant loss of the contralateral allele. 
 
Figure 2. Antitumour activity by allocated dose cohort (IIT population): (A) Best 
percentage change from baseline in PSA whilst on allocated treatment; (B) Best 
percentage change from baseline in sum of target lesions (RECIST 1.1) whilst on 
allocated treatment; (C) Radiographic Progression-Free Survival; (D) Swimmers plot of 
time on treatment for each patient, indicating periods of treatment interruptions, dose 
reductions or dose-escalations (in the 300mg dose cohort).   
 
Figure 3. Antitumour activity by gene subgroup (IIT population, pooled 300mg and 
400mg BID cohorts): (A) Best percentage change from baseline in PSA whilst on 
allocated treatment; (B) Best percentage change from baseline in sum of target lesions 
(RECIST 1.1) whilst on allocated treatment; (C) Radiographic Progression-Free 
Survival; (D) Swimmers plot of time on treatment for each patient.  
(*) indicate patients with different mutations qualifying for more than one subgroup. 
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Table 1. Baseline characteristics of TOPARP-B patients in the ITT population, 
presented by dose cohort 
 
Total (N=98) 
Dose group 
300 mg   
(N=49) 
400 mg  
(N=49) 
Age at trial entry, mean (SD) 67.6 (7.6) 67.7 (7.4) 67.4 (7.8) 
Years from initial diagnosis - median 
(Q1-Q3) 
4.6 (2.8-7) 3.5 (2.4-6.4) 5.2 (3.6-7.3) 
Years from diagnosis of CRPC - median 
(Q1-Q3) 
2.6 (1.6-4) 2.4 (1.2-3.7) 3.0 (1.8-4 ) 
Metastatic disease at diagnosis, n (%)       
Yes 49 (50%) 24 (49%) 25 (51%) 
No 45 (45.9%) 24 (49%) 21 (42.9%) 
Not available 4 (4.1%) 1 (2%) 3 (6.1%) 
Gleason score at diagnosis, n (%) 
      
≤7 19 (19.4%) 4 (8.2%) 15 (30.6%) 
≥8 71 (72.4%) 42 (85.7%) 29 (59.2%) 
Not available 8 (8.2%) 3 (6.1%) 5 (10.2%) 
Previous treatment for PC, n (%)       
Prostatectomy 13 (13.3%) 7 (14.3%) 6 (12.2%) 
Radical radiotherapy 43 (43.9%) 22 (44.9%) 21 (42.9%) 
Biphosphonates 4 (4.1%) 2 (4.1%) 2 (4.1%) 
Radium 223 14 (14.3%) 6 (12.2%) 8 (16.3%) 
Docetaxel 98 (100%) 49 (100%) 49 (100%) 
Cabazitaxel 37 (37.8%) 15 (30.6%) 22 (44.9%) 
Abiraterone 46 (46.9%) 24 (49%) 22 (44.9%) 
Enzalutamide 56 (57.1%) 27 (55.1%) 29 (59.2%) 
Abiraterone and/or Enzalutamide 88 (89.8%) 43 (87.8%) 45 (91.8%) 
Evidence of progression at trial entry, n 
(%) 
      
PSA only 27 (27.6%) 15 (30.6%) 12 (24.5%) 
Radiographic progression (+/- PSA 
progression) 
71 (72.4%) 34 (69.4%) 37 (75.5%) 
Site of metastatic disease at trial entry, 
n (%) 
(1)        
Lung 8 (8.2%) 4 (8.2%) 4 (8.2%) 
Lymph nodes 66 (67.3%) 34 (69.4%) 32 (65.3%) 
Liver 23 (23.5%) 11 (22.4%) 12 (24.5%) 
Bone 82 (83.7%) 41 (83.7%) 41 (83.7%) 
PSA at trial entry (ng/ml) – median (Q1-
Q3) 
154.8  
(45.5-472.0) 
151.5  
(49.0-446.0) 
158.0  
(45.5-472.0) 
CTC count at trial entry, n (%) n % n % n % 
CTC<5 34 (34.7%) 17 (34.7%) 17 (34.7%) 
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Total (N=98) 
Dose group 
300 mg   
(N=49) 
400 mg  
(N=49) 
CTC >= 5 63 (64.3%) 31 (63.3%) 32 (65.3%) 
Not available 
(2) 1 (1%) 1 (2%) 0 (0%) 
RECIST soft tissue disease, n (%)  
      
Bone lesions only  10 (10.2%) 5 (10.2%) 5 (10.2%) 
Non-measurable disease only (+/- bone 
lesions) 
13 (13.3%) 5 (10.2%) 8 (16.3%) 
Measurable disease (+/- bone lesions) 75 (76.5%) 39 (79.6%) 36 (73.5%) 
DDRga gene subgroup, n (%)
(3) n % n % n % 
BRCA1/2 32 (32.7%) 15 (30.6%) 17 (34.7%) 
ATM 21 (21.4%) 10 (20.4%) 11 (22.5%) 
CDK12 21 (21.4%) 15 (30.6%) 6 (12.4%) 
PALB2 7 (7.1%) 3 (6.1%) 4 (8.2%) 
Other 21 (21.4%) 10 (20.4%) 11 (22.5%) 
Q1: 25% percentile, Q3: 75% percentile 
(1) More than one site could be reported. 
(2) Screening CTC assessment not possible due to CTC kit shortage. Patient allowed to be 
randomised as he had RECIST 1.1 measurable disease; for randomisation CTC assumed <5 but 
patient was unevaluable for CTC response. 
(3) Non-mutually exclusive subgroups: one 300mg cohort patient had BRCA1/2, CDK12 and 
‘Other mutations’, and two 300 mg cohort patients with PALB2 mutations also had other 
mutations (in MSH2 and NBN respectively). 
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Table 2. Overall antitumour activity in patients with DDRga, by dose cohort and by gene subgroup (evaluable population; confirmed 
responses) 
 
  
Composite  
overall response 
RECIST 1.1  
Objective Response 
PSA fall ≥50% CTC conversion 
RECIST 1.1  
or PSA response 
  resp/n RR 95% CI resp/n % 95% CI resp/n % 95% CI resp/n % 95% CI resp/n % 95% CI 
Evaluable patients 43/92 46.7 36.3-57.4 14/70 20.0% 11.4-31.3 30/89 33.7% 24.0-44.5 28/55 50.9% 37.1-64.6 32/92 34.8% 25.1-45.4 
    
 
    
 
  
 
 
 
  
 
  
 
 
  
By dose cohort:   
 
    
 
  
   
  
 
  
  
  
300 mg BID 18/46 39.1 25.1-54.6 6/37 16.2% 6.2-32.0 13/43 30.2% 17.2-46.1 13/27 48.1% 28.7-68.1 13/46 28.3% 16.0-43.5 
400 mg BID 25/46 54.3 39.0-69.1 8/33 24.2% 11.1-42.3 17/46 37.0% 23.2-52.5 15/28 53.6% 33.9-72.5 19/46 41.3% 27.0-56.8 
    
 
    
 
  
   
  
 
  
  
  
By gene subgroup
¥
   
 
    
 
  
   
  
 
  
  
  
BRCA 1/2 25/30 83.3 65.3-94.4 11/21 52.4% 29.8-74.3 23/30 76.7% 57.7-90.1 17/22 77.3% 54.6-92.2 24/30 80.0% 61.4-92.3 
ATM 7/19 36.8 16.3-61.6 1/12 8.3% 0.2-38.5 1/19 5.3% 0.1-26.0 5/10 50.0% 18.7-81.3 2/19 10.5% 1.3-33.1 
CDK12 5/20 25.0 8.7-49.1 0/18 0.0% 0-18.5* 0/20 0.0% 0-16.8* 5/12 41.7% 15.2-72.3 0/20 0.0% 0-16.8* 
PALB2 4/7 57.1 18.4-90.1 2/6 33.3% 4.3-77.7 4/6 66.7% 22.3-95.7 0/2 0.0% 0-84.2* 4/7 57.1% 18.4-90.1 
Other 4/20 20.0 5.7-43.7 0/17 0.0% 0-19.5* 2/17 11.8% 1.5-36.4 3/11 27.3% 6.0-61.0 2/20 10.0% 1.2-31.7 
Resp/n: number of observed responses / number of evaluable patients; RR: response rate, 95% CI: 95% confidence interval. *One-sided exact binomial 95% confidence intervals 
¥
Non-mutually exclusive subgroups: One patient treated at 300mgs BID had BRCA1/2, CDK12 & ‘Other mutations’ (300mg); two further 300 mg patients had both PALB2 & ‘Other 
mutations’. These patients have been included in analysis for each subgroup separately. For the gene subgroup analyses, dose cohorts have been pooled. 
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Table 3 – Treatment emergent adverse events, by dose cohort  
Any grade 1-2 event occurring in ≥10% of patients is reported. All grade 3, 4, and 5 events are 
reported. 
*Includes one G5 event (myocardial infarction), grouped with G4 for conciseness.  
  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
Anaemia 16 (32.7) 14 (28.6) 1 (2.0) 19 (38.8) 18 (36.7) 0 
Fatigue 19 (38.8) 3 (6.1) 0 27 (55.1) 4 (8.2) 0 
Back pain 13 (26.5) 4 (8.2) 0 11 (22.4) 3 (6.1) 0 
Nausea 17 (34.7) 1 (2.0) 0 13 (26.5) 0 0 
Platelet count decreased 9 (18.4) 2 (4.1) 1 (2.0) 12 (24.5) 3 (6.1) 0 
Decreased appetite 13 (26.5) 2 (4.1) 0 10 (20.4) 0 0 
Vomiting 10 (20.4) 0 0 15 (30.6) 0 0 
Weight decreased 9 (18.4) 1 (2.0) 0 15 (30.6) 0 0 
Diarrhoea 8 (16.3) 1 (2.0) 0 10 (20.4) 1 (2.0) 0 
Arthralgia 8 (16.3) 1 (2.0) 0 5 (10.2) 4 (8.2) 0 
Hypertension 9 (18.4) 1 (2.0) 0 4 (8.2) 4 (8.2) 0 
Neutrophil count decreased 9 (18.4) 2 (4.1) 0 4 (8.2) 2 (4.1) 1 (2.0) 
Dyspnoea 5 (10.2) 1 (2.0) 0 10 (20.4) 1 (2.0) 0 
Abdominal pain 4 (8.2) 0 0 6 (12.2) 5 (10.2) 1 (2.0) 
Blood creatinine increased 9 (18.4) 0 0 6 (12.2) 0 0 
Oedema peripheral 6 (12.2) 0 0 8 (16.3) 1 (2.0) 0 
Urinary tract infection 3 (6.1) 3 (6.1) 0 6 (12.2) 3 (6.1) 0 
Constipation 7 (14.3) 0 0 7 (14.3) 0 0 
Cough 3 (6.1) 0 0 9 (18.4) 0 0 
Musculoskeletal chest pain 3 (6.1) 0 0 9 (18.4) 0 0 
Musculoskeletal pain 5 (10.2) 1 (2.0) 0 5 (10.2) 1 (2.0) 0 
Hypokalaemia 3 (6.1) 0 0 8 (16.3) 0 0 
Muscular weakness 4 (8.2) 0 0 5 (10.2) 2 (4.1) 0 
WBC count decreased 4 (8.2) 0 0 6 (12.2) 1 (2.0) 0 
AST increased 3 (6.1) 0 1 (2.0) 4 (8.2) 1 (2.0) 0 
ALP increased 3 (6.1) 0 0 5 (10.2) 1 (2.0) 0 
Dysgeusia 6 (12.2) 0 0 3 (6.1) 0 0 
Haematuria 5 (10.2) 0 0 2 (4.1) 2 (4.1) 0 
Influenza like illness 3 (6.1) 0 0 6 (12.2) 0 0 
Muscle spasms 3 (6.1) 0 0 6 (12.2) 0 0 
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  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
GGT increased 3 (6.1) 0 0 2 (4.1) 2 (4.1) 1 (2.0) 
Lower resp. tract infection 4 (8.2) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Lymphocyte count decreased 2 (4.1) 1 (2.0) 0 3 (6.1) 2 (4.1) 0 
Pyrexia 4 (8.2) 2 (4.1) 0 2 (4.1) 0 0 
ALT increased 2 (4.1) 0 0 3 (6.1) 2 (4.1) 0 
Groin pain 3 (6.1) 0 0 2 (4.1) 2 (4.1) 0 
Dizziness 2 (4.1) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Spinal cord compression 0 1 (2.0) 0 0 5 (10.2) 0 
Blood bilirubin increased 1 (2.0) 0 0 3 (6.1) 0 1 (2.0) 
Cellulitis 2 (4.1) 0 0 2 (4.1) 1 (2.0) 0 
Pain 1 (2.0) 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Hydronephrosis 1 (2.0) 2 (4.1) 0 0 1 (2.0) 0 
Hyponatraemia 0 1 (2.0) 0 2 (4.1) 1 (2.0) 0 
Myocardial infarction 0 1 (2.0) 2 (4.1)* 0 1 (2.0) 0 
Acute kidney injury 1 (2.0) 0 1 (2.0) 1 (2.0) 0 0 
Hyperkalaemia 0 1 (2.0) 0 2 (4.1) 0 0 
Rectal haemorrhage 0 1 (2.0) 0 1 (2.0) 1 (2.0) 0 
Amylase increased 0 0 0 1 (2.0) 1 (2.0) 0 
Atrial fibrillation 0 0 0 1 (2.0) 1 (2.0) 0 
Circulatory collapse 0 2 (4.1) 0 0 0 0 
Confusional state 1 (2.0) 1 (2.0) 0 0 0 0 
Femoral neck fracture 0 1 (2.0) 0 1 (2.0) 0 0 
Femur fracture 0 0 0 0 2 (4.1) 0 
Mobility decreased 1 (2.0) 0 0 0 1 (2.0) 0 
Pneumonia 0 0 0 0 2 (4.1) 0 
Presyncope 1 (2.0) 0 0 0 1 (2.0) 0 
Pulmonary embolism 0 1 (2.0) 0 0 1 (2.0) 0 
Respiratory tract infection 1 (2.0) 1 (2.0) 0 0 0 0 
Abdominal infection 0 1 (2.0) 0 0 0 0 
Acute myeloid leukaemia 0 0 1 (2.0) 0 0 0 
Arthritis bacterial 0 1 (2.0) 0 0 0 0 
Bronchitis 0 1 (2.0) 0 0 0 0 
Cauda equina syndrome 0 0 0 0 1 (2.0) 0 
Embolism 0 0 0 0 1 (2.0) 0 
Enterocolitis infectious 0 0 0 0 1 (2.0) 0 
Febrile neutropenia 0 0 0 0 1 (2.0) 0 
Hip fracture 0 1 (2.0) 0 0 0 0 
Intestinal obstruction 0 0 0 0 1 (2.0) 0 
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  300mg (N=49) 400mg (N=49) 
MedDRA preferred term G2 G3 G4* G2 G3 G4 
Jaundice 0 0 0 0 1 (2.0) 0 
Neutropenic sepsis 0 0 0 0 1 (2.0) 0 
Pyelonephritis 0 0 0 0 1 (2.0) 0 
Radiculopathy 0 0 0 0 1 (2.0) 0 
Renal colic 0 1 (2.0) 0 0 0 0 
Sepsis 0 0 0 0 0 1 (2.0) 
Ureteric obstruction 0 1 (2.0) 0 0 0 0 
Urosepsis 0 1 (2.0) 0 0 0 0 
Vascular pseudoaneurysm 0 0 1 (2.0) 0 0 0 
Vision blurred 0 1 (2.0) 0 0 0 0 
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RESEARCH IN CONTEXT 
Evidence before this study 
Trials for advanced prostate cancer have rarely pursued molecular stratification, and 
none of the drugs approved up to date for metastatic prostate cancer care have a 
validated companion biomarker. Before starting this study, several genomic landscape 
studies were published describing an enrichment for aberrations in DNA repair genes in 
metastatic prostate cancers (studies identified in Pubmed, searching for “prostate 
cancer”, “genomics”, “biopsy”, between 2010 and 2015). Preclinical and clinical studies 
identified in Pubmed (search for “cancer”, “PARP” and “BRCA” or “DNA repair” 
between 2005 and 2019) have established a correlation between different DNA repair 
defects and sensitivity to PARP inhibition in different tumour types, leading to drug 
approvals in ovarian and breast cancer. In the TOPARP-A trial, we identified an 
association between somatic alterations in DNA repair genes and antitumour activity of 
olaparib in 49 patients with metastatic prostate cancer. Other clinical trials of PARP 
inhibitors in prostate cancer were identified using ClinicalTrials.gov website, searching 
for “prostate cancer” and “PARP”. 
 
Added value of this study 
To our knowledge, this is the first ever prospective clinical trial for a genomically-
defined population of metastatic prostate cancers. TOPARP-B aims to clinically qualify, 
for the first time, a predictive biomarker for treating metastatic prostate cancers. 
TOPARP-B also assessed different doses of olaparib, and correlated different genomic 
aberrations and antitumour activity. This study has confirmed the antitumour activity of 
olaparib against metastatic prostate cancer with defective DNA repair, secondary to 
either germline or somatic gene inactivation. 
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Implications of all the available evidence 
Randomised phase III trials for DNA repair defective prostate cancers are now ongoing 
based on these data. Our results, if confirmed in registration studies, would support 
implementing tumour genomic testing in clinical practice for treatment stratification in 
advanced prostate cancer.  
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